IPP Bureau
Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings
By IPP Bureau - January 28, 2026
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Trelegy Ellipta gets green light in China for adults with uncontrolled asthma
By IPP Bureau - January 28, 2026
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access
By IPP Bureau - January 28, 2026
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Eastman & Kolmar Korea join forces to deliver biodegradable beauty breakthroughs
By IPP Bureau - January 28, 2026
The collaboration will center on expanding access to Eastman’s Esmeri technology
Ionis and Otsuka score EU nod for DAWNZERA, offering new hope for rare HAE patients
By IPP Bureau - January 28, 2026
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Pangea Laboratory teams with Gene Solutions to bring AI-driven cancer tests to US patients
By IPP Bureau - January 28, 2026
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
Parse Biosciences unveils integrated immune profiling in Trailmaker Platform
By IPP Bureau - January 28, 2026
The new functionality complements Parse’s existing Evercode immune products
Truvian Health bags FDA clearance for CBC on TruVerus System
By IPP Bureau - January 28, 2026
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
EU green light to IntraBio’s AQNEURSA for rare neurological disease Niemann-Pick Type C
By IPP Bureau - January 28, 2026
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Hester receives manufacturing license for inactivated avian influenza vaccine for poultry
By IPP Bureau - January 27, 2026
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
By IPP Bureau - January 25, 2026
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Amway India launches ‘Beyond Biotin’ Nutrilite Biotin C Plus to support skin, hair, nail health
By IPP Bureau - January 24, 2026
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
Yugap Wellness bolsters scientific leadership with Dr Satish Singh appointment
By IPP Bureau - January 24, 2026
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report
By IPP Bureau - January 24, 2026
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
